TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $50.25 Average PT from Brokerages

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have been assigned a consensus rating of “Moderate Buy” from the five brokerages that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $50.25.

Several research firms have commented on TGTX. JPMorgan Chase & Co. upped their target price on shares of TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. B. Riley raised TG Therapeutics to a “strong-buy” rating in a report on Tuesday, November 4th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of TG Therapeutics in a research note on Wednesday, October 8th. HC Wainwright began coverage on TG Therapeutics in a research report on Monday, October 6th. They set a “buy” rating and a $60.00 price target for the company. Finally, Wall Street Zen raised TG Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday.

Insider Buying and Selling

In other TG Therapeutics news, Director Sagar Lonial sold 20,852 shares of the firm’s stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $32.24, for a total transaction of $672,268.48. Following the transaction, the director owned 94,061 shares of the company’s stock, valued at approximately $3,032,526.64. This trade represents a 18.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 10.64% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Ameritas Advisory Services LLC acquired a new position in shares of TG Therapeutics during the second quarter valued at approximately $25,000. Johnson Financial Group Inc. acquired a new position in shares of TG Therapeutics during the 2nd quarter valued at $25,000. Bessemer Group Inc. raised its stake in shares of TG Therapeutics by 117.1% in the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 486 shares in the last quarter. Salomon & Ludwin LLC acquired a new stake in shares of TG Therapeutics in the third quarter valued at $34,000. Finally, Stone House Investment Management LLC acquired a new stake in shares of TG Therapeutics in the third quarter valued at $36,000. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Stock Performance

TG Therapeutics stock opened at $32.24 on Thursday. TG Therapeutics has a 12 month low of $25.28 and a 12 month high of $46.48. The company has a fifty day moving average price of $33.91 and a two-hundred day moving average price of $34.68. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.86 and a quick ratio of 2.96. The company has a market cap of $5.12 billion, a PE ratio of 87.14 and a beta of 1.95.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share for the quarter, topping the consensus estimate of $0.24 by $2.19. The firm had revenue of $161.71 million for the quarter, compared to analyst estimates of $152.12 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The firm’s revenue for the quarter was up 92.7% on a year-over-year basis. During the same period last year, the company earned $0.02 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS. Research analysts expect that TG Therapeutics will post 0.08 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.